Comparative Benchmarking
In the context of the broader market, RVPH competes directly with industry leaders such as BFRI and TOVX. With a market capitalization of $8.40M, it holds a significant position in the sector. When comparing efficiency, RVPH's gross margin of N/A stands against BFRI's 82.40% and TOVX's N/A. Such benchmarking helps identify whether Reviva Pharmaceuticals Holdings Inc is trading at a premium or discount relative to its financial performance.
